Yahoo
OTC Markets OTCQX - Delayed Quote USD

Integrated BioPharma, Inc. (INBP)

0.1700 0.0000 (0.00%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for INBP
  • Previous Close 0.1700
  • Open 0.1737
  • Bid 0.1553 x 2000000
  • Ask 0.2400 x 550000
  • Day's Range 0.1737 - 0.1737
  • 52 Week Range 0.1400 - 0.4200
  • Volume 900
  • Avg. Volume 8,690
  • Market Cap (intraday) 5.28M
  • Beta (5Y Monthly) 0.48
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0900
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

ir.ibiopharma.com

134

Full Time Employees

June 30

Fiscal Year Ends

Packaged Foods

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

INBP
52.78%
S&P 500 (^GSPC)
7.76%

1-Year Return

INBP
41.38%
S&P 500 (^GSPC)
9.77%

3-Year Return

INBP
37.04%
S&P 500 (^GSPC)
68.96%

5-Year Return

INBP
83.81%
S&P 500 (^GSPC)
57.04%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.48%

  • Return on Assets (ttm)

    -6.73%

  • Return on Equity (ttm)

    -14.96%

  • Revenue (ttm)

    43.87M

  • Net Income Avi to Common (ttm)

    -2.84M

  • Diluted EPS (ttm)

    -0.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.47M

  • Total Debt/Equity (mrq)

    17.42%

  • Levered Free Cash Flow (ttm)

    2.8M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: